Management of the child with type 1 diabetes

Pediatric Endocrinology: Obesity, Diabetes Mellitus, Insulin Resistance, and Hypoglycemia

Volumn , Issue , 2006, Pages 101-124

  Escobar, Oscar ^a   Drash, Allan L ^a   Becker, Dorothy J ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867316059     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (121)

1. James T. History of medicine. Paulesco. S Afr Med J 1992; 82(2):123-125.
2. Murray I. Paulesco and the isolation of insulin. J Hist Med Allied Sci 1971; 26(2):150-157.
3. Bliss M. The discovery of insulin. McClelland, Stewart, eds. Chicago: University of Chicago Press, 1982.
4. Porksen N, Hollingdal M, Juhl C, et al. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes 2002; 51(suppl 1):S245-S254.
5. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36(11-12):852-858.
6. Leon DD, Crutchlow MF, Ham JY, et al. Role of glucagonlike peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 2005; 146(10): 4224-4233.
7. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first and second phase insulin secretion in response to intravenous glucose in subjects with Type 2 diabetes. J Clin Endocrinol Metab 2005; 90(11):5991-5997.
8. Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 2005; 128(2):149-157.
9. Feldman JM. Pathophysiology of diabetes mellitus. In: Galloway JA, Potvin JH, Shuman CR, eds. Diabetes Mellitus. 9th. Indianapolis: Eli Lilly, 1988:28-44.
10. Gerich JA. Hormonal control of homeostasis. In: Galloway JA, Potvin JH, Shuman CR, eds. Diabetes Mellitus. 9th. Indianapolis: Eli Lilly, 1988:45-64.
11. Diabetes Research in Children Network (DirecNet) Study Group. A multi-center study of the accuracy of the one touch ultra home glucose meter in children with Type 1 diabetes. Diabetes Technol Ther 2003; 5(6):933-941.
12. Tang Z, Du X, Louie RF, et al. Effects of drugs on glucose measurements with handheld glucose meters and a portable glucose analyzer. Am J Clin Pathol 2000; 113(1): 75-86.
13. Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMS in children with Type 1 diabetes: results of the diabetes research in children network (DirecNet) accuracy study. Diabetes Technol Ther 2003; 5:781-789.
14. Diabetes Research in Children Network (DirecNet) Study Group. Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. Diabetes Technol Ther 2005; 7:109-114.
15. Diabetes Research in Children Network (DirecNet) Study Group. Lack of accuracy of continuous glucose sensors in healthy, nondiabetic children: results of the Diabetes Research in Children Network (DirecNet) accuracy study. J Pediatr 2004; 144(6):770-775.
16. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor. A randomized trial. Diabetes Care 2006; 29(1):44-50.
17. Little RR, Wiedmeyer HM, England JD, et al. International standardization of glycohemoglobin measurements: practical application. Clin Chem 1993; 39(11 Pt 1):2356.
18. Little RR, Rohlfing CL, Wiedmeyer HM, et al., NGSP Steering Committee. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001; 47(11):1985-1992.
19. Schnedl WJ, Krause R, Halwachs-Baumann G, et al. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care 2000; 23(3): 339-344.
20. Diabetes Research in Children Network (DirecNet) Study Group. Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) study. PediatrDiabetes 2005; 6(1):13-16.
21. Sicard DA, Taylor JR. Comparison of point-of-care HbA1c test versus standardized laboratory testing. Ann Pharmacother 2005; 39(6):1024-1028.
22. Galloway JA. New directions in drug development: mixtures, analogs, modeling. Diabetes care 1993; 16(3):16-23.
23. Chance RE, Frank BH. Research, development, production and safety of biosynthetic human insulin. Diabetes Care 1993; 16(3):133-142.
24. Saudek CD. Future developments in insulin delivery systems. Diabetes Care 1993; 16(3):122-132.
25. Laube BL. Treating diabetes with aerosolized insulin. Chest 2001; 120(suppl 3):99S-106S.
26. Tamborlane WV, Bonfig W, Boland E. Recent advances in treatment of youth with Type 1 diabetes: better care through technology. Diabet Med 2001; 18(11):864-870.
27. Steiner S, Pfutzner A, Wilson BRO, et al. TechnosphereTM/Insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002; 110(1):17-21.
28. Gerber RA, Cappelleri JC, Kourides IA, et al. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001; 24(9):1556-1559.
29. Skyler JS, CefaluWT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357(9253):331-335.
30. Skyler JS, Weinstock RS, Raskin P, et al. Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28(7):1630-1635.
31. Schade DS, Santiago JV, Skyler JS, et al. Intensive Insulin Therapy. Amsterdam: Excerpta Medica, 1983.
32. Drash AL. Clinical care of the diabetic child. Chicago: Year Book Medical Publishers, 1987.
33. Santiago JV. Insulin therapy in the last decade: a pediatric perspective. Diabetes Care 1993; 16(3):143-154.
34. Becker DJ. Management of insulin-dependent diabetes mellitus in children and adolescents. Curr Opin Pediatr 1991; 3:710-723.
35. Rother KT, Levitsky LL. Diabetes mellitus during adolescence. Adolescent endocrinology. Endocrinol Metab Clin North Am 1993; 22:553-572.
36. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998; 128(7):517-523.
37. Becker D. Individualized insulin therapy in children and adolescents with type 1 diabetes. Acta Pediatr 1998; 425(suppl):20-24.
38. Cryer P. Human insulin and hypoglycemia unawareness. Diabetes Care 1990; 13:536-538.
39. Orchard TJ, Maser RE, Becker DJ, et al. Human insulin use and hypoglycemia. Insights from the Pittsburgh Epidemiology Study. Diabetic Med 1991:469-471.
40. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogs and their potential in the management of diabetes mellitus. Diabetologia 1999; 42:1151-1167.
41. Brange J. The new era of biotech insulin analogues. Diabetologia 1997; 40:S48-S53.
42. Berger M, Heinemann L. Are presently available insulin analogues clinically beneficial? Diabetologia 1997; 40: S91-S96.
43. Danne T, Becker RHA, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005; 28:2100-2105.
44. Chase HP, Lockspeiser T, Perry B, et al. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in Type 1 diabetes. Diabetes Care 2001; 24:430-434.
45. Mohn A, Matyka KA, Harris DA, et al. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Diabetes Care 1999; 22:27-32.
46. Danne T, Deisst D, HopfenmullerW, et al. Experience with insulin analogs in children. Horm Res 2002; 57:46-53.
47. Weinzimer SA, Doyle EA, Tamborlane WV. Disease management in the young diabetic patients: glucose monitoring, coping skills, and treatment strategies. Clin Pediatr 2005; 44:393-403.
48. Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004; 114:1601-1605.
49. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive therapy for type 1 diabetes. Diabetes Care 2000; 23(5):639-643.
50. Chase HP, Dixon B, Pearson JS, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine hagedorn insulin. J Pediatr 2003; 143:737-740.
51. Home P, Bartley P, Russell-Jones D, et al. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27(5):1081-1087.
52. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53(6):1614-1620.
53. Danne T, Lüpke K, Walte K, et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003; 26:3087-3092.
54. International Society for Pediatric And Adolescent Diabetes. Consensus Guidelines. The Netherlands: Medical forum International for the International society for Pediatric and Adolescent Pediatrics, 2000:1.
55. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329(14):977-986.
56. Rovet JF, Ehrlich RM. The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study. J Pediatr 1999; 134:503-506.
57. Becker D. Intensive diabetes therapy in childhood: is it achievable? Is it desirable? Is it safe? J Pediatr 1999; 134:392-394.
58. Ludvigsson J, Bolli GB. Intensive insulin treatment in diabetic children. Diabetes Nutr Metab 2001; 14(5): 292-304.
59. White NH, Cleary PA, DahmsW, et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139(6): 804-812.
60. Heinemann L, Richter B. Clinical pharmacology of human insulin. Diabetes Care 1993; 16(3):90-100.
61. Becker DJ, Kerensky KM, Transue D, et al. Current status of pump therapy in childhood. Acta Pediatr Jpn 1984; 6:347-358.
62. American Diabetes Association Clinical Education Series: insulin infusion pump therapy. In: Intensive Diabetes Management. 2nd ed. Alexandria, Virginia: American Diabetes Association Inc, 1998:99-120.
63. Kaufman FR, Halvorson M, Fisher L, et al. Insulin pump therapy in Type 1 patients. J Pediatr Endocrinol Metab 1999; 12(3):759-764.
64. Anderson B, Ho J, Brackett J, et al. Parental involvement in diabetes management tasks: relationship to blood glucose monitoring adherence and metabolic control in young adolescents with insulin dependent diabetes mellitus. J Pediatr 1997; 130:257-265.
65. Steindel BS, Roe TR, Costin G, Carlson M, Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract 1995; 27(3):199-204.
66. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22(11):1779-1784.
67. Maniatis AK, Klingensmith GJ, Slover RH. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001; 107(2):351-356.
68. Zinman B. Insulin regimens and strategies for IDDM. Diabetes Care 1993; 16(3):24-28.
69. Bolli GB, Peniello G, Carmine G, et al. Nocturnal blood glucose control in Type 1 diabetes mellitus. Diabetes Care 1993; 16(3):71-89.
70. Tansey MJ, Tsalikian E, Beck RW, et al. The Diabetes Research in Children Network (DirecNet) Study Group. The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. Diabetes Care 2006; 29(1):20-25.
71. Tsalikian E, Mauras N, Beck RW, et al. Diabetes Research In Children Network Direcnet Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr 2005; 147(4):528-534.
72. Diabetes Care 1994; 17:519-522.
73. Institute of Medicine of the National Academies: Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington, D.C: National Academy Press, 2002:1-8 http://www.iom.edu/Object.File/Master/4/154/0.pdf.
74. Perrotti N, Santoro D, Genovese S, et al. Effect of digestible carbohydrates on glucose control in insulin-dependent patients with diabetes. Diabetes Care 1984; 7:354-359.
75. Strychar IM, Blain E, Rivard M, et al. Association between dietary adherence measures and glycemic control in outpatients with type 1 diabetes mellitus and normal serum lipid levels. J Am Diet Assoc 1998; 98:76-79.
76. Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002; 25:148-198.
77. Bantle JP, Laine DC, Thomas JW. Metabolic effects of dietary fructose and sucrose in types I and II diabetic subjects. JAMA 1986; 256:3241-3246.
78. Bantle JP, Swanson JE, Thomas W, et al. Metabolic effects of dietary fructose in diabetic subjects. Diabetes Care 1992; 15:1468-1476.
79. Bantle JP, Swanson JE, Thomas W, Laine DC. Metabolic effects of dietary sucrose in type II diabetic subjects. Diabetes Care 1993; 16:1301-1305.
80. Orchard TJ, Forrest KY, Kuller LH, et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2001; 24(6): 1053-1059.
81. Fried LF, Forrest KY, Ellis D, et al. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001; 15(3):113-119.
82. Collier G, McLean A, O’Dea K. Effect of co-ingestion of fat on the metabolic responses to slowly and rapidly absorbed carbohydrates. Diabetologia 1984; 26:50-54.
83. Toeller M, Buyken A, Heitkamp G, et al. The EURODIAB IDDM Complications Study. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1999; 40:1219-1226.
84. LaPorte R, Dorman JS, Tajima N, et al. Pittsburgh insulindependent diabetes mellitus morbidity and mortality study: physical activity and diabetic complications. Pediatric 1986; 78:1027-1033.
85. Moy CS, LaPorte RE, Dorman J, et al. Physical activity, insulin dependent diabetes mellitus and death. Am J Epidemiol 1993; 137(1):74-81.
86. Zinman B. Exercise in the patient with diabetes mellitus. In: Galloway JA, Potvin JH, Schuman CR, eds. Diabetes Mellitus. 9th. Indianapolis: Eli Lilly, 1988:215-224.
87. Arslanian S, Nixon PA, Becker D, et al. Impact of physical fitness and glycemic control on in vivo insulin action in adolescents with IDDM. Diabetes Care 1990; 13:9-15.
88. Rigla M, Sanchez-Quesada JL, et al. Effect of physical exercise on lipoprotein(a) and low-density lipoprotein modifications in type 1 and type 2 diabetic patients. Metabolism 2000; 49(5):640-647.
89. Chase P, Crews K, Garg S. Outpatient management vs in-hospital management of children with new-onset diabetes. Clinical Pediatrics 1992; 31(8):450-456.
90. Swift P, Hearnshaw J, Botha J, et al. A decade of diabetes: keeping children out of hospital. Br J Med 1993; 307: 96-98.
91. Lee P. An outpatient-focused program for childhood diabetes: design, implementation, and effectiveness. J Tex Med 1992; 88(7):64-68.
92. The Pennsylvania State University The Graduate School Department of health education comparing outpatient to inpatient diabetes education for newly diagnosed pediatric patients: an exploratory study. A Thesis in Health Education by Linda M. Siminerio Copyright 1998 Linda M. Siminerio Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy May 1998.
93. Siminerio LM, Charron-Prochownik D, Banion C, et al. Comparing outpatient and inpatient diabetes education for newly diagnosed pediatric patients. Diabetes Educ 1999; 25(6):895-906.
94. Charron-Prochownik D, Maihle T, Siminerio L, et al. Outpatient versus inpatient care of children newly diagnosed with IDDM. Diabetes Care 1997; 20(4):657-660.
95. Ryan C, Gurtunca N, Becker D. Hypoglycemia: a complication of diabetes therapy in children. Pediatr Clin North Am 2005; 52:1705-1733.
96. American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28:1245-1249.
97. Dunger DB, Sperling MA, Acerini CL, et al. ESPE; LWPES. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004; 89(2):188-194.
98. Ryan CM, Becker DJ. Hypoglycemia in children with type 1 diabetes mellitus. Risk factors, cognitive function, and management. Endocrinol Metab Clin North Am 1999; 28(4):883-900.
99. Cronin CC, Shanahan F. Insulin-dependent diabetes mellitus and coeliac disease. Lancet 1997; 349:1096-1097.
100. Hummel M, Ziegler AG, Bonifacio E. Type 1 diabetes mellitus, celiac disease and their association-lessons from antibodies. J Pediatr Endocrinol Metab 2001; 14(suppl 1):607-610.
101. Schuppan D, Hahn EG. Celiac disease and its link to type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001; 14(suppl 1):597-605.
102. Shanahan F, Mckenna R, McCarthy CF, et al. Coeliac disease and diabetes mellitus: a study of 24 patients with HLA typing. QJM 1982; 51:329-335.
103. Bonifacio E, Ziegler AG, Hummel M, et al. Gluten: is it also a determinant of islet autoimmunity? Diabetes Metab Rev 1998; 14(3):258-259.
104. Drash AL, Becker DJ. Behavioral issues in patients with diabetes mellitus, with special emphasis on the child and adolescent. In: Rifkin H, Porte D, eds. Ellenberg and Rifkin’s Diabetes Mellitus Theory and Practice. 4th. New York: Elsevier, 1990:992-934.
105. Kelly SD, Howe CJ, Hendler JP, et al. Disordered eating behaviors in youth with type 1 diabetes. Diabetes Educ 2005; 31(4):572-583.
106. Mannucci E, Rotella F, Ricca V, et al. Eating disorders in patients with type 1 diabetes: a meta-analysis. J Endocrinol Invest 2005; 28(5):417-419.
107. Lane PH. Pediatric aspects of diabetic kidney disease. Adv Chronic Kidney Dis 2005; 12(2):230-235.
108. Chiarelli F, Trotta D, Verrotti A, et al. Treatment of hypertension and microalbuminuria in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2002; 3(2):113-124.
109. Tsamasiros J, Bartsocas CS. Transition of the adolescent from the children’s to the adults’ diabetes clinic. J Pediatr Endocrinol Metab 2002; 15(4):363-367.
110. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm 2005; 62(13):1359-1364.
111. DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28(8):1922-1928.
112. Harsch IA. Inhaled insulins: their potential in the treatment of diabetes mellitus. Treat Endocrinol 2005; 4(3): 131-138.
113. New York Times January 28, 2006.
114. Cooper GJ, Willis AC, Clark A, et al. Purification and characterization of a peptide from amyloid-rich pancreases of Type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84:8628-8632.
115. Gedulin BR, Rink TJ, Young AA. Dose response for glucagonostatic effect of amylin in rats. Metabolism 1997; 46:67-70.
116. Sansom, M, Szarka LA, Camilleri M, et al. Pramlintide, an amylin analog selectively delays gastric emptying: potential role for vagal inhibition. Am J Physiol 2000; 278:G946-G951.
117. Bhavsar S, Watkins J, Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 1998; 64:557-561.
118. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004; 12(4):661-668.
119. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26(3):784-790.
120. Ratner R, Whitehouse F, Fineman MS, et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes 2005; 113(4):199-204.
121. Heptulla RA, Rodriguez LM, Bomgaars L, et al. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005; 54(4):1100-1107.